Loading...
XSHG600479
Market cap616mUSD
Dec 25, Last price  
10.75CNY
1D
-0.46%
1Q
5.91%
Jan 2017
-18.19%
Name

ZhuZhou QianJin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600479 chart
P/E
14.04
P/S
1.18
EPS
0.77
Div Yield, %
3.32%
Shrs. gr., 5y
0.19%
Rev. gr., 5y
2.68%
Revenues
3.80b
-5.66%
604,927,872665,825,902602,686,103679,777,224801,429,486904,270,114979,443,7661,256,527,2711,583,422,7331,972,855,0852,194,240,4702,446,684,0742,864,885,5123,182,743,7923,328,553,9633,525,238,1223,626,966,8083,663,844,6134,026,278,5933,798,485,329
Net income
320m
+5.92%
45,387,75559,863,87871,778,673173,619,322129,892,010130,913,57986,382,77982,821,345120,164,483123,767,862105,092,91092,959,634149,428,673207,758,270255,355,306294,313,213297,071,596302,063,356302,508,846320,405,834
CFO
454m
-38.11%
18,454,15976,501,036120,122,93979,263,36137,204,11773,541,73039,129,91622,578,202197,816,674137,632,243183,342,68867,484,546140,879,318283,466,753383,466,469155,493,890542,373,092485,573,058733,472,924453,932,674
Dividend
Jun 27, 20240.35 CNY/sh
Earnings
May 21, 2025

Profile

ZhuZhou QianJin Pharmaceutical Co.,Ltd produces and sells pharmaceutical products in China. The company provides gynecology, pediatrics, beauty, antimicrobial, circulatory, endocrine, specialty, digestive, nervous, and cardiovascular products, as well as traditional Chinese medicines It offers its products in various forms, including tablets, capsules, granules, pills, decoctions, powders, and solution. The company also provides ginger tea; feminine hygiene products; and wine. ZhuZhou QianJin Pharmaceutical Co.,Ltd was founded in 1993 and is headquartered in Zhuzhou, China.
URL
http://www.qjyy.com/
IPO date
Mar 12, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,798,485
-5.66%
4,026,279
9.89%
3,663,845
1.02%
Cost of revenue
2,832,620
3,382,916
3,104,242
Unusual Expense (Income)
NOPBT
965,866
643,363
559,603
NOPBT Margin
25.43%
15.98%
15.27%
Operating Taxes
65,403
57,550
58,682
Tax Rate
6.77%
8.95%
10.49%
NOPAT
900,463
585,813
500,920
Net income
320,406
5.92%
302,509
0.15%
302,063
1.68%
Dividends
(149,539)
(257,884)
(418,507)
Dividend yield
3.29%
6.42%
7.97%
Proceeds from repurchase of equity
(3,382)
BB yield
0.07%
Debt
Debt current
73,243
79,476
88,640
Long-term debt
69,926
77,529
105,073
Deferred revenue
38,042
44,441
51,271
Other long-term liabilities
45,136
7,094
7,094
Net debt
(2,102,344)
(1,574,689)
(1,176,003)
Cash flow
Cash from operating activities
453,933
733,473
485,573
CAPEX
(43,989)
Cash from investing activities
574,468
122,148
Cash from financing activities
(202,003)
FCF
995,305
836,964
493,829
Balance
Cash
1,997,900
1,731,693
1,369,716
Long term investments
247,613
Excess cash
2,055,588
1,530,379
1,186,524
Stockholders' equity
2,210,046
2,275,966
2,196,903
Invested Capital
1,111,452
1,389,146
1,685,104
ROIC
72.02%
38.11%
29.55%
ROCE
30.26%
21.95%
19.40%
EV
Common stock shares outstanding
422,532
418,507
418,507
Price
10.77
12.19%
9.60
-23.51%
12.55
45.25%
Market cap
4,550,667
13.27%
4,017,668
-23.51%
5,252,264
45.25%
EV
3,085,406
3,043,050
4,625,808
EBITDA
1,069,520
738,963
645,537
EV/EBITDA
2.88
4.12
7.17
Interest
5,965
2,215
2,115
Interest/NOPBT
0.62%
0.34%
0.38%